BioSpace News Archive

Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference

The American Red Cross and the National Football League are teaming up during January, National Blood Donor Month, to score big for patients in need by encouraging football fans and blood donors to give now.

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Alison Lawton, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference

OrthoPediatrics Corp. announced that it has completed the sale of substantially all of the assets related to the adult product offering of Vilex in Tennessee, Inc. to Vilex LLC, an affiliate of Squadron Capital LLC.

Emmes today announced that the U.S. Food and Drug Administration (FDA) has approved a prescription-only medical device used to estimate the weight of infants who are up to 90 days of age.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of $40-$50 million in cumulative total contract value (TCV) and has expanded its personalized ctDNA minimal residual disease (MRD) and monitoring intellectual property portfolio with 8 newly allowed or issued patents in 2019.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dara Grantham Wright as Executive Vice President and President of the Clinical Diagnostics Group, effective January 1, 2020.

Martin Gilligan joins from Celgene Corporation where he led marketing, market access and business development for the Inflammation & Immunology Franchise

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has signed agreements to acquire Parcus Medical,

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference